The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Philip D. Lister

Department of Medical Microbiology and Immunology

Creighton University School of Medicine

2500 California Plaza




Name/email consistency: high



  • Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, USA. 2007 - 2009
  • Center for Research in Anti-Infectives and Biotechnology Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, NE 68178, USA. 1998 - 2009


  1. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Lister, P.D., Wolter, D.J., Hanson, N.D. Clin. Microbiol. Rev. (2009) [Pubmed]
  2. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae. Lister, P.D. Postgrad. Med (2008) [Pubmed]
  3. Carbapenems in the USA: focus on doripenem. Lister, P.D. Expert. Rev. Anti. Infect. Ther (2007) [Pubmed]
  4. The role of pharmacodynamic research in the assessment and development of new antibacterial drugs. Lister, P.D. Biochem. Pharmacol. (2006) [Pubmed]
  5. Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs. Lister, P.D., Wolter, D.J., Wickman, P.A., Reisbig, M.D. J. Antimicrob. Chemother. (2006) [Pubmed]
  6. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Lister, P.D., Wolter, D.J. Clin. Infect. Dis. (2005) [Pubmed]
  7. Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. Lister, P.D. Antimicrob. Agents Chemother. (2002) [Pubmed]
  8. Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. Lister, P.D. Diagn. Microbiol. Infect. Dis. (2002) [Pubmed]
  9. Chromosomally-encoded resistance mechanisms of Pseudomonas aeruginosa: therapeutic implications. Lister, P.D. Am. J. Pharmacogenomics (2002) [Pubmed]
  10. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Lister, P.D. Clin. Infect. Dis. (2001) [Pubmed]
  11. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. Lister, P.D., Sanders, C.C. J. Antimicrob. Chemother. (2001) [Pubmed]
  12. Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin. Lister, P.D., Gardner, V.M., Sanders, C.C. Antimicrob. Agents Chemother. (1999) [Pubmed]
  13. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Lister, P.D., Sanders, C.C. Antimicrob. Agents Chemother. (1999) [Pubmed]
  14. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. Lister, P.D., Sanders, C.C. J. Antimicrob. Chemother. (1999) [Pubmed]
  15. Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa. Lister, P.D., Sanders, W.E., Sanders, C.C. Antimicrob. Agents Chemother. (1998) [Pubmed]
WikiGenes - Universities